Male Urinary Device Addresses Patient Management Challenges

A next-generation external catheter reduces the risk of catheter-associated urinary tract infections (CAUTIs), device leakage, and healthcare-acquired skin injuries.

The ReliaFit Male Urinary Device is designed with a gentle, hydrocolloid seal that conforms to the skin, a flexible faceplate that fits any size penis (including uncircumcised and retracted anatomy), and a vent to improve drainage. It also includes Mastisol, a non-water-soluble adhesive with a proven safety profile that increase the secure fit of the device to the patient's anatomy. For additional securement and improved performance, a product set including the proprietary securement device CathGrip is available.


The design of the ReliaFit Male Urinary Device makes it is easy to apply, providing the patient with the confidence that it will remain in place for an extended period of time, and also reducing the Nurses' need to frequently assess placement and securement. The ReliaFit device is manufactured through a partnership between Eloquest (Detroit, MI, USA) and Bioderm (Largo, FL, USA), and can be connected to most leg or bedside urine drainage bags.

“ReliaFit is an integral part of our specialized portfolio of easy-to-use products that improve patient outcomes and reduce treatment costs,” said Tim O'Halla, executive vice president and COO of Eloquest. “Based on its performance, clinicians prefer ReliaFit. We believe that this device will revolutionize urinary management by reducing infection rates and improving patient care and satisfaction.”

Hospital acquired infections (HAIs) are the fifth leading cause of death in hospitals, and urinary tract infections (UTIs) make up about 40% percent of all HAIs. Of those, 80% of UTIs are attributable to indwelling urinary catheterization. In addition, the use of antimicrobials to treat CAUTIs may contribute to the development of antimicrobial resistance. In the US alone, CAUTIs cost USD 424-451 million dollars per year. The increased cost includes longer hospital stays extended by an average of two to four days.

Related Links:
Eloquest
Bioderm